Targeted therapy in breast cancer (Homo sapiens)

From WikiPathways

Revision as of 00:01, 12 November 2024 by Eweitz (Talk | contribs)
Jump to: navigation, search


Description

"Trastuzumab and pertuzumab inhibit HER2 signaling by binding to the extracellular domain of HER2. Lapatinib, neratinib, tucatinib, and pyrotinib inhibit HER signaling by binding to the intracellular tyrosine kinase domain of the Her family members. EGFR epidermal growth factor receptor, HER human epidermal growth factor receptor, MEK MAP kinase kinase, ERK MAP kinase, PI3K phosphoinositide 3-kinases (adapted from “HER2 Signaling Pathway”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates)". Source: Figure F1, https://pmc.ncbi.nlm.nih.gov/articles/PMC9281252/. Derived from PFOCR, https://pfocr.wikipathways.org/figures/PMC9281252__12032_2022_1749_Fig1_HTML.html.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

  1. Demir Cetinkaya B, Biray Avci C; ''Molecular perspective on targeted therapy in breast cancer: a review of current status.''; Med Oncol, 2022 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
135813view00:21, 12 November 2024EweitzFix PI3K node
135812view00:10, 12 November 2024EweitzOntology Term : 'luminal epithelial cell of mammary gland' added !
135811view00:10, 12 November 2024EweitzOntology Term : 'mammary gland epithelial cell' added !
135810view00:07, 12 November 2024EweitzOntology Term : 'drug pathway' added !
135809view00:07, 12 November 2024EweitzOntology Term : 'breast cancer pathway' added !
135808view00:07, 12 November 2024EweitzOntology Term : 'breast cancer' added !
135807view00:05, 12 November 2024EweitzEmphasize drug interactions
135806view00:05, 12 November 2024EweitzIdentify tucatinib
135805view00:02, 12 November 2024EweitzRemove less relevant comments
135804view00:01, 12 November 2024EweitzRefine layout
135803view00:00, 12 November 2024EweitzRefine layout
135802view23:57, 11 November 2024EweitzLabel organelle, economize layout
135801view23:33, 11 November 2024EweitzAdd more interactions
135800view23:19, 11 November 2024EweitzAdd drugs, phosphorylation states
135799view22:31, 11 November 2024EweitzAdd cell, surface protein dimers
135798view22:09, 11 November 2024EweitzImport AKT family
135797view22:04, 11 November 2024EweitzImprove organization
135796view21:52, 11 November 2024EweitzImport PI3K family
135794view19:56, 11 November 2024EweitzImport parts of RAS / MAPK pathway
135793view19:50, 11 November 2024EweitzNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
AKT1GeneProductENSG00000142208 (Ensembl)
AKT2GeneProductENSG00000105221 (Ensembl)
AKT3GeneProductENSG00000117020 (Ensembl)
EGFRGeneProductENSG00000146648 (Ensembl)
ERBB2GeneProductENSG00000141736 (Ensembl)
ERBB3GeneProductENSG00000065361 (Ensembl)
ERBB4GeneProductENSG00000178568 (Ensembl)
HRASGeneProductENSG00000174775 (Ensembl)
KRASGeneProductENSG00000133703 (Ensembl)
LapatinibMetaboliteCHEBI:49603 (ChEBI)
MAP2K1GeneProductENSG00000107356 (Ensembl)
MAP2K2GeneProductENSG00000101418 (Ensembl)
MAP2K3GeneProductENSG00000107958 (Ensembl)
MAP2K4GeneProductENSG00000115669 (Ensembl)
MAP2K5GeneProductENSG00000138015 (Ensembl)
MAP2K6GeneProductENSG00000129652 (Ensembl)
MAP2K7GeneProductENSG00000118907 (Ensembl)
MAPK1GeneProductENSG00000100030 (Ensembl) Literature notes: "No specific YAP inhibitors are currently in clinical use, however, Truong et al. demonstrated that combined therapy with trametinib MEK1/2 inhibition and the lysosome inhibitor chloroquine increased cytotoxicity while indirectly decreasing YAP nuclear localization and transcriptional activity (Feng et al., 2019; Truong et al., 2020). Other groups have proposed GNAQ overactivation of ERK1/2 or MEK1/2 as a driver of UM, but inhibitors of this pathway alone are typically insufficient to stop progression and the degree of MAPK activation is widely heterogeneous within tumor sites"
MAPK3GeneProductENSG00000102882 (Ensembl) Literature notes: "No specific YAP inhibitors are currently in clinical use, however, Truong et al. demonstrated that combined therapy with trametinib MEK1/2 inhibition and the lysosome inhibitor chloroquine increased cytotoxicity while indirectly decreasing YAP nuclear localization and transcriptional activity (Feng et al., 2019; Truong et al., 2020). Other groups have proposed GNAQ overactivation of ERK1/2 or MEK1/2 as a driver of UM, but inhibitors of this pathway alone are typically insufficient to stop progression and the degree of MAPK activation is widely heterogeneous within tumor sites"
NRASGeneProductENSG00000213281 (Ensembl)
NeratinibMetaboliteCHEBI:61397 (ChEBI)
PIK3C2AGeneProductENSG00000011405 (Ensembl)
PIK3C2BGeneProductENSG00000133056 (Ensembl)
PIK3C2GGeneProductENSG00000139144 (Ensembl)
PIK3CAGeneProductENSG00000121879 (Ensembl)
PIK3CBGeneProductENSG00000051382 (Ensembl)
PIK3CDGeneProductENSG00000171608 (Ensembl)
PIK3CGGeneProductENSG00000105851 (Ensembl)
PIK3R1GeneProductENSG00000145675 (Ensembl)
PIK3R2GeneProductENSG00000105647 (Ensembl)
PIK3R3GeneProductENSG00000117461 (Ensembl)
PIK3R4GeneProductENSG00000196455 (Ensembl)
PIK3R6GeneProductENSG00000276231 (Ensembl)
PertuzumabMetaboliteDB06366 (DrugBank)
PyrotinibMetaboliteDB14993 (DrugBank)
RAF1GeneProductENSG00000132155 (Ensembl)
TrastuzumabMetaboliteDB00072 (DrugBank)
TucatinibMetabolite

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP5496"
Personal tools